In many countries around the world, scepticism around generic drugs endures, in spite of the fact that they are “bioequivalent” to (chemically the same as) their branded counterparts. But this attitude seems to be shifting as much cheaper generic drugs make up an increasing share of the global market, receiving a larger proportion of drug spend and, in so doing, saving countries billions of dollars
